Witte Hanno, Biersack Harald, Kopelke Svenja, Rades Dirk, Merz Hartmut, Bernard Veronica, Lehnert Hendrik, Gebauer Niklas
Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Department of Radiation Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Oncotarget. 2018 Apr 13;9(28):19613-19622. doi: 10.18632/oncotarget.24701.
While various studies characterized clinical and prognostic properties of diffuse large B-Cell lymphoma (DLBCL) and transformed indolent lymphomas, the clinicopathological features of indolent lymphoma and simultaneous secondary transformation upon initial diagnosis (ssDLBCL) are insufficiently established. Between 2010 and 2017, 247 consecutive patients admitted to our institution and treated for DLBCL were investigated for composite histology of ssDLBCL-type. Upon systematical histopathological evaluation composite histology was identified in 22/247 cases (8.9%). The predominant histology of the underlying indolent lymphoma was follicular lymphoma of variable grading (I-IIIA; 81.8%) whereas marginal zone lymphoma represented a minor sub group (18.2%). Clinicopathological investigation revealed a high degree of concordance between ssDLBCL and DLBCL upon initial diagnosis and clinical courses were shown to be strikingly similar. The predominant fraction of ssDLBCL were germinal center derived lymphomas (GCB-type) with a trend towards a superior outcome compared with non-GCB-type ssDLBCL. Additionally, we demonstrate a significant adverse prognostic impact of an underlying indolent lymphoma component other than follicular-type lymphoma (e.g. marginal zone lymphoma). Moreover, the frequency of double-hit (DHL) or double-expressor lymphomas (DEL) appears to be low. Our findings provide substantial insight into the behavior of ssDLBCL, highlight the ramifications of the concurrent high-grade fraction within indolent lymphomas and underline therapeutic efficacy of R-CHOP type immunochemotherapy in the majority of ssDLBCL patients.
虽然多项研究描述了弥漫性大B细胞淋巴瘤(DLBCL)和转化型惰性淋巴瘤的临床及预后特征,但惰性淋巴瘤及初诊时同时发生继发性转化(ssDLBCL)的临床病理特征尚未完全明确。2010年至2017年期间,对我院收治并接受DLBCL治疗的247例连续患者进行了ssDLBCL型复合组织学调查。经过系统的组织病理学评估,在22/247例病例(8.9%)中发现了复合组织学。基础惰性淋巴瘤的主要组织学类型为不同分级的滤泡性淋巴瘤(I-IIIA级;81.8%),而边缘区淋巴瘤占较小的亚组(18.2%)。临床病理调查显示,ssDLBCL与初诊时的DLBCL高度一致,临床病程也极为相似。ssDLBCL的主要部分是生发中心来源的淋巴瘤(GCB型),与非GCB型ssDLBCL相比,其预后有更好的趋势。此外,我们证明了除滤泡型淋巴瘤(如边缘区淋巴瘤)外的基础惰性淋巴瘤成分具有显著的不良预后影响。而且,双打击(DHL)或双表达淋巴瘤(DEL)的发生率似乎较低。我们的研究结果为ssDLBCL的行为提供了重要见解,突出了惰性淋巴瘤中同时存在的高级别成分的影响,并强调了R-CHOP型免疫化疗在大多数ssDLBCL患者中的治疗效果。